Login to Your Account



Pharming Shares Fall on CHMP's Second Rebuff of Rhucin in HAE

By Cormac Sheridan


Wednesday, March 26, 2008
Pharming Group NV lost nearly 25 percent of its value March 20 on news that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) was standing by its original decision to adopt a negative opinion on an application for its hereditary angioedema (HAE) drug Rhucin. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription